Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma

Luciano J. Costa, Shaji K Kumar, Stephanie A. Stowell, Shari J. Dermer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The mobilization of hematopoietic stem cells can be a limiting factor for transplantation, yet little is known about how the availability of novel mobilizing agents has affected the practices of oncologists and transplant specialists.

Methods: US-based oncologists (n = 48) and transplant specialists (n = 46) were separately surveyed with a partial overlap of assessed information.

Results: More transplant specialists than oncologists believed that the time between referral and first consultation is adequate (89.1% vs 54.2%; P < .001). The presence of comorbidities was the most common reason for patients not being referred for transplantation. Among oncologists, 31.3% avoided cyclophosphamide and 16.7% avoided lenalidomide to prevent mobilization impairment in patients with multiple myeloma (MM). Chemotherapy mobilization for MM was used by 23.9% of transplant specialists due to higher CD34+ yields and by 21.7% due to its anti-MM effect. In non-Hodgkin lymphoma (NHL), 26.1% of transplant specialists used chemotherapy mobilization due to higher CD34+ yields, and 26.1% collected hematopoietic stem cells on the rebound prior to chemotherapy. With regard to plerixafor use in MM, 36.9% of transplant specialists reported that they did not use it, and 28.3% said they reserved it for second mobilization. In NHL, 4.3% of transplant specialists reported not using plerixafor, and 39.1% reserved it for second mobilization.

Conclusions: Educational needs were identified to promote adequate referral for transplantation as well as successful and cost-effective methods for the mobilization of hematopoietic stem cells.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalCancer Control
Volume22
Issue number1
StatePublished - Jan 1 2015

Fingerprint

Autologous Transplantation
Hematopoietic Stem Cells
Multiple Myeloma
Non-Hodgkin's Lymphoma
Transplants
Hematopoietic Stem Cell Mobilization
Transplantation
Drug Therapy
Referral and Consultation
Cyclophosphamide
Comorbidity
Costs and Cost Analysis
Oncologists

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma. / Costa, Luciano J.; Kumar, Shaji K; Stowell, Stephanie A.; Dermer, Shari J.

In: Cancer Control, Vol. 22, No. 1, 01.01.2015, p. 87-94.

Research output: Contribution to journalArticle

Costa, Luciano J. ; Kumar, Shaji K ; Stowell, Stephanie A. ; Dermer, Shari J. / Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma. In: Cancer Control. 2015 ; Vol. 22, No. 1. pp. 87-94.
@article{389c798134fa41aa953949a42a47445e,
title = "Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma",
abstract = "Background: The mobilization of hematopoietic stem cells can be a limiting factor for transplantation, yet little is known about how the availability of novel mobilizing agents has affected the practices of oncologists and transplant specialists.Methods: US-based oncologists (n = 48) and transplant specialists (n = 46) were separately surveyed with a partial overlap of assessed information.Results: More transplant specialists than oncologists believed that the time between referral and first consultation is adequate (89.1{\%} vs 54.2{\%}; P < .001). The presence of comorbidities was the most common reason for patients not being referred for transplantation. Among oncologists, 31.3{\%} avoided cyclophosphamide and 16.7{\%} avoided lenalidomide to prevent mobilization impairment in patients with multiple myeloma (MM). Chemotherapy mobilization for MM was used by 23.9{\%} of transplant specialists due to higher CD34+ yields and by 21.7{\%} due to its anti-MM effect. In non-Hodgkin lymphoma (NHL), 26.1{\%} of transplant specialists used chemotherapy mobilization due to higher CD34+ yields, and 26.1{\%} collected hematopoietic stem cells on the rebound prior to chemotherapy. With regard to plerixafor use in MM, 36.9{\%} of transplant specialists reported that they did not use it, and 28.3{\%} said they reserved it for second mobilization. In NHL, 4.3{\%} of transplant specialists reported not using plerixafor, and 39.1{\%} reserved it for second mobilization.Conclusions: Educational needs were identified to promote adequate referral for transplantation as well as successful and cost-effective methods for the mobilization of hematopoietic stem cells.",
author = "Costa, {Luciano J.} and Kumar, {Shaji K} and Stowell, {Stephanie A.} and Dermer, {Shari J.}",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "22",
pages = "87--94",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "1",

}

TY - JOUR

T1 - Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma

AU - Costa, Luciano J.

AU - Kumar, Shaji K

AU - Stowell, Stephanie A.

AU - Dermer, Shari J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: The mobilization of hematopoietic stem cells can be a limiting factor for transplantation, yet little is known about how the availability of novel mobilizing agents has affected the practices of oncologists and transplant specialists.Methods: US-based oncologists (n = 48) and transplant specialists (n = 46) were separately surveyed with a partial overlap of assessed information.Results: More transplant specialists than oncologists believed that the time between referral and first consultation is adequate (89.1% vs 54.2%; P < .001). The presence of comorbidities was the most common reason for patients not being referred for transplantation. Among oncologists, 31.3% avoided cyclophosphamide and 16.7% avoided lenalidomide to prevent mobilization impairment in patients with multiple myeloma (MM). Chemotherapy mobilization for MM was used by 23.9% of transplant specialists due to higher CD34+ yields and by 21.7% due to its anti-MM effect. In non-Hodgkin lymphoma (NHL), 26.1% of transplant specialists used chemotherapy mobilization due to higher CD34+ yields, and 26.1% collected hematopoietic stem cells on the rebound prior to chemotherapy. With regard to plerixafor use in MM, 36.9% of transplant specialists reported that they did not use it, and 28.3% said they reserved it for second mobilization. In NHL, 4.3% of transplant specialists reported not using plerixafor, and 39.1% reserved it for second mobilization.Conclusions: Educational needs were identified to promote adequate referral for transplantation as well as successful and cost-effective methods for the mobilization of hematopoietic stem cells.

AB - Background: The mobilization of hematopoietic stem cells can be a limiting factor for transplantation, yet little is known about how the availability of novel mobilizing agents has affected the practices of oncologists and transplant specialists.Methods: US-based oncologists (n = 48) and transplant specialists (n = 46) were separately surveyed with a partial overlap of assessed information.Results: More transplant specialists than oncologists believed that the time between referral and first consultation is adequate (89.1% vs 54.2%; P < .001). The presence of comorbidities was the most common reason for patients not being referred for transplantation. Among oncologists, 31.3% avoided cyclophosphamide and 16.7% avoided lenalidomide to prevent mobilization impairment in patients with multiple myeloma (MM). Chemotherapy mobilization for MM was used by 23.9% of transplant specialists due to higher CD34+ yields and by 21.7% due to its anti-MM effect. In non-Hodgkin lymphoma (NHL), 26.1% of transplant specialists used chemotherapy mobilization due to higher CD34+ yields, and 26.1% collected hematopoietic stem cells on the rebound prior to chemotherapy. With regard to plerixafor use in MM, 36.9% of transplant specialists reported that they did not use it, and 28.3% said they reserved it for second mobilization. In NHL, 4.3% of transplant specialists reported not using plerixafor, and 39.1% reserved it for second mobilization.Conclusions: Educational needs were identified to promote adequate referral for transplantation as well as successful and cost-effective methods for the mobilization of hematopoietic stem cells.

UR - http://www.scopus.com/inward/record.url?scp=84924769529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924769529&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 87

EP - 94

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 1

ER -